Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
OncoMed Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: OMED
Industry Pharmaceutical
Founded University of Michigan August 2004; 13 years ago (2004-08)
Founders
  • Michael Clarke
  • Max Wicha
Headquarters Redwood City, California, United States
Key people
  • Paul Hastings (CEO)
  • John Lewicki (R&D chief)
  • Chuck Alaimo (Operations director)
Revenue US$24,700,000 (2012)
Total assets US$207,600,000  (2016)
Number of employees
  • 83 (2013)
  • 47 (2007)
Website www.oncomed.com
Footnotes / references

OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.

Oncomed was incorporated in Delaware in 2004.

In 2007, Oncomed consolidated its operations located in Mountain View and Palo Alto, California onto the single headquarters campus at Seaport Centre in Redwood City. One of the buildings on the new campus was the former home of NeXT.

In 2012, OncoMed sponsored the USAN nonproprietary name vantictumab for a human IgG2 anti-Frizzled antibody, an anti-cancer therapeutic. In the same year, the company sponsored the USAN name demcizumab for a human IgG2 anti-DLL4 antibody, also an anti-cancer therapeutic.

In 2014, OncoMed entered into an anti-cancer stem cell therapeutic development agreement with Celgene encompassing demcizumab and five other biologics from OncoMed's pipeline.

As of 2013, co-founder Max Wicha was the director of the University of Michigan Comprehensive Cancer Center and remained a consultant to OncoMed, while co-founder Michael Clarke had taken up a position at Stanford University.

In 2013, OncoMed had at least two direct competitors, both public American companies: Stemline Therapeutics and Verastem. By 2014, the list of firms pursuing therapies targeting cancer stem cells had grown to include Boston Biomedical (a subsidiary of Dainippon Sumitomo Pharma), GlaxoSmithKline, Astellas Pharma, Sanofi (the American subsidiary) and Pfizer; however, Stemline and Verastem remain the only two competitors solely focused on cancer stem cells. One analyst holds that OncoMed is the best positioned of the three companies focused on the cancer stem cell area.

As of January 2017, Oncomed had seven clinical-stage drugs in development and four discovery-stage investigations; no OncoMed therapies have made it to market yet. Two candidate drugs being co-developed with Bayer, ipafricept and vantictumab, showed in mid-2014 indications of "causing mild-to-moderate bone-related side effects" among Phase I clinical trial participants, an observation which led the company to halt enrollment and dosing in the trials, and which contributed to a sharp decline in share price.

Demcizumab, OMP-305B83, and OMP-131R10 are being developed in collaboration with Celgene. Tarextumab and brontictuzumab are being developed in collaboration with GlaxoSmithKline Vantictumab and ipafricept are being developed in collaboration with Bayer.

As of 2013, OncoMed's chief executive officer (CEO) was Paul Hastings, who took the post in 2006. As of 2007, the company's head of R&D was John Lewicki, and the director of operations was Chuck Alaimo.

While serving as OncoMed's CEO, Hastings was also a member of the board of directors for the California Healthcare Institute and the Bay Area Biosciences Association, as well as chairing the board of the Biotechnology Industry Organization. Hastings education includes a bachelor's degree in pharmacy from the University of Rhode Island.

Investment goal date:
Dividends reinvested
OncoMed Pharmaceuticals, Inc. OMED report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-07
--
--
Q4 2017
2018-02-21
--
--
Q3 2017
2017-11-02
--
--
Q3 2017
2017-11-02
-0.2800
0.0000
Q2 2017
2017-08-02
-0.4000
-0.4000
Q1 2017
2017-05-08
-0.6100
-0.6100
Q4 2016
2017-03-08
-0.6000
-0.6000
Q3 2016
2016-11-01
-0.7700
-0.7700
Q2 2016
2016-08-09
-0.9100
-0.9100
Q1 2016
2016-05-05
-0.9000
-0.9000
Q4 2015
2016-03-10
-0.8200
-0.8200
Q3 2015
2015-11-05
-0.8100
-0.8100
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ADAMS STREET PARTNERS LLC
1839730
Alyeska Investment Group, L.P.
706240
AMERIPRISE FINANCIAL INC
680450
BlackRock Fund Advisors
1195897
BlackRock Inc.
1694365
BlackRock Institutional Trust Company, N.A.
380570
BVF INC/IL
1760489
FMR LLC
985438
FRANKLIN RESOURCES INC
963700
GOLDMAN SACHS GROUP INC
582730
Iguana Healthcare Management, LLC
490000
PRIMECAP MANAGEMENT CO/CA/
1906600
RENAISSANCE TECHNOLOGIES LLC
533600
STATE STREET CORP
352312
Vanguard Group, Inc
945485
Major Shareholders
Name Relationship
Total Shares
Holding stocks
LASERSOHN JACK W
0.6200% (185709)
MASI / OMED /
GLAXOSMITHKLINE PLC
8.7600% (2607546)
MORGENTHALER PARTNERS VII LP
8.4300% (2509671)
GBIM / OMED /
VERTICAL GROUP LP
2.7000% (803694)
OMED /
PRESIDIO MANAGEMENT GROUP VIII L L C
0.1900% (56528)
ATRC / OMED /
KARSEN PERRY A
0.0300% (10000)
PAKIANATHAN DEEPIKA
0.0600% (18940)
Pollard-Knight Denise
6.5300% (1943509)
BIOD / IDIX / OMED /
HASTINGS PAUL J
0.2600% (76188)
OMED / PCRX / PRTO / RLYP /
LVP GP I, LLC
0.1100% (33703)
OMED /
Patel Sunil
0.2300% (68336)
LGND / OMED /
Hoey Timothy
0.2600% (77225)
OMED /
Dupont Jakob
0.0700% (20642)
OMED /
Waddill William D.
0.1000% (29758)
CALA / OMED / PTGX /
Lewicki John A.
0.2400% (70412)
OMED /
Gurney Austin
0.2700% (80817)
OMED /
Hager Alicia J.
0.2000% (58647)
OMED /
Woody James N.
0.1100% (33703)
OMED / TLOG /
Broderick James W.
8.4300% (2509671)
OMED /
Lasky Laurence
0.0300% (10332)
OMED /
% ()